ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1581

Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
Abstract Number: 0945

Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Abstract Number: 0070

Neutrophils Transiting Through Megakaryocytes During Emperipolesis Exhibit Distinct Fates and Acquire the Capacity to Guide Other Neutrophils via MK Trails
Abstract Number: 1617

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 1360

New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study
Abstract Number: 1972

NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis
Abstract Number: 1854

NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Abstract Number: 1092

NMR-Based Serum Metabolomics, Is It Different in Clinico-Serological Clusters of Idiopathic Inflammatory Myositis?
Abstract Number: 1173

No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort
Abstract Number: 1631

No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Abstract Number: 1896

No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 1995

Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study
Abstract Number: 0485

Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk
Abstract Number: 1234

Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab
Abstract Number: 0973

Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].